fbpx

Remember the days when medical marijuana was entering the mainstream as states all across the nation were just beginning to legalize?

Tiny pot companies were going public and literally exploding overnight. I’m talking thousands of percentage points in just a very short period of time. 

Like Tilray. This pot company went public in July 2018 at $17 and skyrocketed to $300 by September, only to come crashing down to just below its initial offering price. 

But there were countless others, and cannabis investing minted a whole new generation of millionaires.

Investors literally lined their pockets off the excitement of people all throughout the U.S. and Canada— seniors especially — who were looking for more holistic solutions for pain relief over those provided by Big Pharma. 

But if you think you missed out on explosive gains on companies going public and literally upending the healthcare system as we know it, I’ve got news for you.

The pot stock “green rush” may have already come and gone, but psychedelic medicines are the next big thing

Now, this may sound a bit far fetched to you. But I want to take some time today to give you the inside scoop on this budding industry, as you could be among the first round of investors to ride this brand new wave. 

Already, two psychedelic companies, MindMed (OTCMKTS: MMEDF, NEO: MMED) and Champignon Brands (CNSX: SHRM) have gone public in Canada. 

I’m anticipating many more of these companies, including Field Trip Health, to follow and as legislation supporting the medical potential of psychedelic medicines opens up in the months and years to come. 

Believe it or not, 2020 is already believed by some to be the landmark year for psychedelic stocks.

Frankly, I wouldn’t be surprised if some of the already successful cannabis companies scramble to get a piece of this action quite soon as well.

By joining IPO Payday, you’ll be among the first to find out about how I’m potentially making moves on any of these psychedelic stocks as they arise. 

So without further ado, let’s take a closer look at this dizzying new industry, a few of the front runners, and where I think the profit potential is the years, even mere months, ahead.

 

Here’s What Psychedelic Medicines Are… And Why You Should Care

 

While psychedelics may have been known for centuries by people in indigenous cultures from their profound healing effects, the medical mainstream is only just waking up to their true potential. 

They’ve come a long way really, ever since radical Harvard psychologists Timothy Leary and Richard Alpert initially started experimenting with them way back in the day. 

Some of the psychedelic substances attracting interest from the scientific community include psilocybin (the chemical in psychedelic mushrooms), lysergic acid diethylamide (LSD), methylenedioxymethamphetamine (MDMA), and ketamine. 

These substances have the potential to treat a range of conditions, including anxiety, depression, addiction, and post-traumatic stress disorder (PTSD).

While the use of psychedelics is not yet recreationally legal in North America, progressive states like California, Colorado, Vermont, and Washington D.C. are currently making headway to decriminalize them. 

These efforts to decriminalize psychedelics are following the exact same footprints laid out by the pot industry just a few years ago. 

And while efforts to legally recreation the substances may still be a work in progress, organizations are already legally permitted to do research on them. 

You may be aware that Johns Hopkins opened the Center for Psychedelic and Consciousness Research in September 2019, thanks to $17 million in private donations. 

You can’t make money by the truckload by investing in Johns Hopkins now or ever, but a handful of private and public companies are currently offering that possibility. 

What’s interesting about some of these companies as well is that their medicines may be non-hallucinatory. 

Just as CBD’s have become a medical resource for those people seeking relief but not looking to get high, many of these psychedelic medicines may provide some of the same benefits without the “trip.”

 

MindMed: Psychedelic Inspired Medicines 

 

According to its website, MindMed “discovers, develops, and deploys psychedelic inspired medicines to alleviate suffering and improve health.” 

The company has been conducting clinical trials in a couple of different areas. 

They are currently in the middle of phase II clinical trials in non-hallucinogenic micro-doses of LSD to treat ADHD, as well as an FDA clinical trial of 18-MC (from Ibogaine) to treat opioid addiction.

The founder and co-chief executive, JR Rahn, said recently, “Our ambition is to be one of the first publicly listed neuro-pharmaceutical companies developing psychedelic medicines.” 

Just this past month, they accomplished that. MindMed officially IPOed on Canada’s NEO exchange in March under the ticket MMED. 

The company is not yet generating revenue but has a valuation of around $50 million. 

Notable figures in this enterprise include Bruce Linton of a medical marijuana company, Canopy Growth Corp, who will serve as MindMed’s director, as well as Shark Tank star Kevin O’Leary who’s already a key investor.  

 

Champignon: Medicinal Mushrooms in Your Coffee and Tea

 

Champignon is a medicinal mushrooms company that focuses its efforts on developing and distributing medical mushrooms and consumer packaged goods. 

It’s line of specialty products include organic and non-genetically modified mushroom formulations such as “Vitality Superteas.”

The company even partnered with Drip Coffee Social Ltd. to infuse their mushroom extracts into cold brew coffee products. 

More recently, the company plans to venture into psilocybin mushrooms research in quarter 3 of 2020 through clinical trials. 

The company is already scaling up the production of its pharmaceutical-grade psilocybin in order to complete these clinical trials. 

So far, Roardman Investors Corp. is the most notable investor in this new psychedelic brand. 

Champignon Brands recently conducted its IPO under the ticker symbol SHRM on the Canadian Stock Exchange (CNSX).

It offered 18 million common shares at $0.15 per share to acquire proceeds of more than $2.8 million.

 

Field Trip Health: Psychedelic Therapies that Bring You to Life

 

Looking ahead, Field Trip Health, while not yet public, is hot on the psychedelic IPO trail. 

This company aims to provide legal psychedelic therapies that heal depression and has health centers that provide patients with a comfortable and safe environment for treatments. 

Patents at these health centers have the opportunity to work with a team of medical professionals that will guide them through treatments developed by some of the world’s leading psychiatrists, physicians, and therapists. 

Treatments include ketamine-enhanced therapy sessions, which help bring about transpersonal experiences that help break thought patterns and old habits. 

Field Trip Health just successfully closed on private placement on February 6 for $8.5 million. 

This series A financing was led by the company’s founders, Singhal Health Foundation, and some Silicon Valley investors. 

I’ll certainly be keeping an eye out for Field Trip Health in the months ahead, as it’s a strong contender to become one of the first psychedelic companies to IPO in the U.S. 

If it does IPO and I decide to hop on board, my IPO Payday subscribers will be the first to know.

Author:
Ben Sturgill

Ben leads two services at RagingBull. IPO Payday can help you pinpoint, position, and profit from IPOs. In Daily Profit Machine Ben guides day and swing traders to profit by trading the SPY Index. Ben hosts the RagingBull.com weekly podcast WealthWise where he shares thoughts on wealth and success with traders, businesspeople, entrepreneurs, and experts to uncover and share the wisdom needed to live a wealthy life.

Learn More

Leave your comment